Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Galectin Therapeutic (GALT)

Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 189,551
  • Shares Outstanding, K 62,148
  • Annual Sales, $ 0 K
  • Annual Income, $ -41,070 K
  • 60-Month Beta 0.72
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade GALT with:

Options Overview Details

View History
  • Implied Volatility 145.89% ( +29.36%)
  • Historical Volatility 77.04%
  • IV Percentile 69%
  • IV Rank 23.34%
  • IV High 598.48% on 10/13/23
  • IV Low 8.08% on 09/14/23
  • Put/Call Vol Ratio 0.08
  • Today's Volume 27
  • Volume Avg (30-Day) 90
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 13,592
  • Open Int (30-Day) 13,737

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.75 +10.91%
on 05/13/24
3.78 -19.31%
on 04/29/24
-0.24 (-7.29%)
since 04/24/24
3-Month
1.80 +69.44%
on 02/26/24
4.27 -28.54%
on 04/12/24
+1.17 (+62.23%)
since 02/23/24
52-Week
1.28 +138.28%
on 06/26/23
4.27 -28.54%
on 04/12/24
+1.27 (+71.35%)
since 05/24/23

Most Recent Stories

More News
Rating the Top 4 Unusually Active Call Options From Thursday’s Trading

The top four unusually active call options in Thursday trading had an average Vol/OI ratio of 52.25. While that’s not very high, each has compelling reasons to buy. Here's why.

JPM : 200.71 (+1.92%)
FTDR : 35.19 (+1.00%)
GALT : 3.05 (unch)
KKR : 106.43 (+2.36%)
CPRI : 34.63 (-0.49%)
TPR : 42.30 (+2.27%)
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

GALT : 3.05 (unch)
GLMD : 0.3874 (-0.67%)
VKTX : 62.75 (+1.92%)
ETNB : 8.14 (-0.49%)
IVA : 3.46 (-3.31%)
SGMT : 4.82 (+2.55%)
TERN : 6.00 (+2.39%)
NVO : 136.04 (+0.35%)
IQV : 229.60 (+1.11%)
MDGL : 229.58 (-2.24%)
Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' Now

Galectin Therapeutics Inc. (GALT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement...

GALT : 3.05 (unch)
Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024

NORCROSS, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin...

GALT : 3.05 (unch)
Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022

NORCROSS, Ga., June 21, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3,...

GALT : 3.05 (unch)
Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress

NORCROSS, Ga., May 23, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...

GALT : 3.05 (unch)
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

NORCROSS, Ga., May 16, 2022 (GLOBE NEWSWIRE) --  Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...

GALT : 3.05 (unch)
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y

Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.

CPRX : 15.87 (-0.31%)
GALT : 3.05 (unch)
ONTX : 0.9953 (-0.47%)
SLNO : 41.16 (-0.02%)
Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update

NORCROSS, Ga., March 31, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...

GALT : 3.05 (unch)
Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference

NORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...

GALT : 3.05 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring...

See More

Key Turning Points

3rd Resistance Point 3.27
2nd Resistance Point 3.18
1st Resistance Point 3.12
Last Price 3.05
1st Support Level 2.97
2nd Support Level 2.88
3rd Support Level 2.82

See More

52-Week High 4.27
Fibonacci 61.8% 3.13
Last Price 3.05
Fibonacci 50% 2.77
Fibonacci 38.2% 2.42
52-Week Low 1.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar